Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Lacey B. Robinson et al.|New England Journal of Medicine|2023Cited by 452
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic EsophagitisIkuo Hirano, Allen Radin, Evan S. Dellon et al.|Gastroenterology|2019Cited by 448
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 100
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut AllergyR. Sharon Chinthrajah, Allen Radin, Sayantani Sindher et al.|Allergy|2024Cited by 33